论文部分内容阅读
目的探讨常规+核苷类抗病毒药物在乙型病毒性肝炎肝硬化患者中的应用价值及其对乙型肝炎病毒脱氧核糖核酸(HBV-DNA)水平、乙型病毒性肝炎e抗原(HBe Ag)转阴率的影响。方法将我院104例乙型肝炎肝硬化患者以随机数字表法分为观察组与对照组,对照组患者行常规治疗,观察组患者对症治疗基础上给予核苷酸类抗病毒药物,比较两组患者的HBV-DNA降幅,HBe Ag转阴率。结果观察组HBV-DNA降低幅度为(5.33±2.34)lg拷贝/ml,明显高于对照组(0.56±0.17)lg拷贝/ml(P<0.05);观察组HBV-DNA转阴率明显较高(P<0.05);观察组HBe Ag转阴率明显较高(P<0.05)。结论常规+核苷酸类抗病毒药物治疗乙型病毒性肝炎肝硬化效果明显,可降低HBV-DNA水平,提高HBe Ag转阴率。
Objective To investigate the value of routine + nucleoside antiviral drugs in patients with hepatitis B cirrhosis and its effect on hepatitis B virus DNA (HBV-DNA), hepatitis B e antigen (HBe Ag ) The impact of negative conversion rate. Methods A total of 104 cases of hepatitis B cirrhosis in our hospital were divided into observation group and control group by random number table. Patients in control group were treated routinely. Nucleotide antiviral drugs were given to patients in observation group on the basis of symptomatic treatment. Group of patients with HBV-DNA decline, HBeAg negative rate. Results The decrease of HBV-DNA in the observation group was (5.33 ± 2.34) lg copies / ml, which was significantly higher than that of the control group (0.56 ± 0.17) lg copies / ml (P <0.05) (P <0.05). The negative rate of HBeAg in the observation group was significantly higher (P <0.05). Conclusion Conventional and nucleotide-based antiviral drugs are effective in treating cirrhosis of patients with viral hepatitis B, which can reduce the level of HBV-DNA and increase the negative rate of HBeAg.